Table 3 SARS-CoV-2 IgG titers between/among groups with different vaccination
From: Impact of comorbidities on the serological response to COVID-19 vaccination in a Taiwanese cohort
1st dose-2nd dose-3rd dose | N (%) | SARS-CoV-2 IgG titer (log BAU/mL, mean (SD)) |
|---|---|---|
AZ-based | 475 (57.6) | 2.98 (0.46)a |
  AZ–AZ–AZ | 1 (0.1) | 3.63 |
  AZ–AZ–Moderna | 323 (39.2) | 3.03 (0.45) |
  AZ–AZ–Medigen | 30 (3.6) | 2.57 (0.34) |
  AZ–AZ–BNT | 121 (14.7) | 2.94 (0.44) |
Moderna-based | 253 (30.7) | 3.34 (0.39)b |
  Moderna–Moderna–AZ | 1 (0.1) | 3.71 |
  Moderna–Moderna–Moderna | 229 (27.8) | 3.38 (0.38) |
  Moderna–Moderna–Medigen | 11 (1.3) | 2.84 (0.31) |
  Moderna–Moderna–BNT | 12 (1.5) | 3.05 (0.37) |
Medigen-based | 20 (2.4) | 3.01 (0.45)c |
  Medigen–Medigen–Moderna | 4 (0.5) | 3.44 (0.41) |
  Medigen–Medigen–Medigen | 10 (1.2) | 2.80 (0.34) |
  Medigen–Medigen–BNT | 6 (0.7) | 3.06 (0.45) |
BNT-based | 33 (4.0) | 3.37 (0.33)d |
  BNT–BNT–Moderna | 15 (1.8) | 3.50 (0.29) |
  BNT–BNT–Medigen | 1 (0.1) | 3.65 |
  BNT–BNT–BNT | 17 (2.1) | 3.24 (0.32) |
Other vaccination combination | 43 (5.2) | 3.00 (0.45) |